Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, were developed using Co.'s ADAPTIR™ modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform. Co.'s ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells. We show 33 historical shares outstanding datapoints in our coverage of APVO's shares outstanding history.
Understanding the changing numbers of APVO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APVO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APVO by allowing them to research APVO shares outstanding history
as well as any other stock in our coverage universe. |
Free APVO Email Alerts:
Video: Shares Outstanding Importance
